Jeffrey A. Jeddeloh
About Jeffrey A. Jeddeloh
Professional Role and Title
Jeffrey A. Jeddeloh serves as the Vice President of Business Development. In this capacity, he is responsible for spearheading strategic initiatives and driving growth opportunities for the company.
Educational Background and Training
Jeffrey A. Jeddeloh holds a PhD from Washington University, along with an MBA from the University of Wisconsin. He completed his postdoctoral training at the US Army's Medical Research Institute for Infectious Diseases, where he focused on developing vaccines. These academic and professional training experiences have provided him with a robust foundation in both scientific research and business strategy.
Experience in Genetic and Vaccine Research
Jeffrey A. Jeddeloh is classically trained as a geneticist. His postdoctoral training involved developing vaccines, a vital experience gained at the US Army's Medical Research Institute for Infectious Diseases. His work in this area underscores his expertise in infectious diseases and vaccine development.
Industry Contributions and Research
Throughout his career, Jeffrey A. Jeddeloh has published over 50 peer-reviewed publications, accruing more than 12,000 citations. His research covers significant areas such as oncology, epigenetics, genetics, and genomics, highlighting his substantial contributions to scientific knowledge in these fields.
Roles in Epigenetic and Genomics Technology Development
At Orion Genomics, Jeffrey A. Jeddeloh spent 6 years building epigenetic biomarker discovery and validation platform technologies. Additionally, he was part of the NimbleGen Systems R&D team at Roche, leading a market development prototyping business. His role in these prominent organizations emphasizes his expertise in advancing genomic and epigenetic technologies.
Corporate Development and Market Strategy
Jeffrey A. Jeddeloh has supported an enzyme-focused startup, DNA Script, in market and corporate development. This experience underscores his skills in corporate strategy, particularly within the biotech startup ecosystem.